Close

Not a member yet? Register now and get started.

lock and key

Sign in to your account.

Account Login

Forgot your password?

CGM & Insulin Pump Market Idea Proposal

CGM & Insulin Pump Market Idea Proposal
 

Are any of the diabetes wearables market’s key players setting themselves apart and gaining significant share?

Report Available: June 3, 2021

 

Blueshift’s ongoing research found the continues glucose monitoring (CGM) and insulin pump market experiencing strong and increasing demand despite the negative impact and volatility the COVID-19 pandemic has had on other medical device companies. The pandemic is driving rapid adoption of telehealth and virtual care as patients and the companies that make devices are all trying to benefit from the significant increase in tech-driven services and wearable devices. In the diabetes space, DXCM, ABT, MDT, TNDM, and PODD have all experienced solid performance and growth, and each has plans for new product launches and collaborations in 2021. What is unknown is if any of these providers can significantly disrupt the current share balance.

 

Observations

  1. CGM and insulin pump market expansion expectations are running high thanks to the explosive adoption and use of telehealth and virtual care during the pandemic. According to a survey from SVB Leerink of endocrinologists and nurse practitioners, CGM patients are projected to jump by 38% in 2021 and 29% in 2022. Another survey by SVB Leerink projects insulin pump use to expand by double-digits. Type 2 diabetics are being targeted as the primary growth driver for CGM devices as that market is large, under-penetrated, and growing.
  2. After delaying the G7 launch due to COVID-19’s disruption of its clinical trials, DXCM said it plans to submit the G7 for FDA approval as soon as possible in 2021 and plans for a limited launch late in the year. The G7 will be thinner, provide longer wear time, be less costly to produce, and is expected to appeal to some of the type 2 patient population.
  3. After launching the Libre 2 in the U.S. in 2020, ABT is planning an update in 2021 to the Libre 3. The new device will be smaller and provide a real-time glucose reading every minute on a compatible mobile app compared to Libre 2’s flash readings.
  4. In the insulin pump market, TNDM’s Control-IQ technology was the first FDA-cleared algorithm for use with a fully interoperable, automated insulin dosing system in 2020. This year the company is expanding the launch of Control-IQ in Canada, Germany, and France. TNDM is also working on a mobile bolusing feature and making progress on its t:sport insulin pump which should be commercialized in early 2022.
  5. MDT is the only provider in the diabetes space offering both a CGM and insulin pump. Plans call for a 2021 U.S. launch of its next-gen system MiniMed 780G pump system which is currently available in Europe. MDT has also entered into a cross-patent agreement with TNDM which should help both companies.
  6. PODD plans a limited launch for its Omnipod 5 insulin pump during the first half of 2021. The company recently presented data at the Endo 2021 meeting, indicating that the Omnipod 5 is highly effective in treating the traditionally hard-to-control pediatric population. The device incorporates the DXCM G6 CGM system.
  7. Seemingly the only headwinds that could disrupt the growth and expansion of the diabetes market is further outbreaks of COVID-19 which would slow device approvals as the FDA has committed to addressing the needs of fighting the pandemic ahead of other device and pharma approvals. There is also an element of the medical community that is questioning the expansion of CGM into the Type 2 diabetes patient population as there is limited evidence that it leads to better outcomes.
  8. Blueshift’s coverage of the diabetes space has been overwhelmingly positive for all the major players with the exception of MDT which was experiencing share losses due to a recall and its older technology. Our 3, 2020 insulin pump report noted that CGM and insulin pump markets are both expected to experience accelerated growth over the next two years, driven by the increasing incidence of diabetes, improved awareness of the disease and its treatments by both providers and patients, technology advancements, collaborations, and DIY organization pressure. Sources discussed growth rates from 10% to 75%. Tossing the extremes, the average expected growth rate was 23%. Past Blueshift coverage of the CGM and insulin pump markets includes our March 26, 2020, report citing DXCM as the leader in the CGM market. The Oct. 23, 2019, report update revealed DXCM’s and TNDM’s growth trends would not be disrupted over the next six to 12 months, and Blueshift’s June 19, 2019, TNDM report and April 25, 2019, DXCM report reflected positive findings.

 

With 2021 pegged as a watershed year for the diabetes wearables market, are any of its key players setting themselves apart and gaining significant share? Which of the current CGM and insulin pump providers is poised for significant share gains or losses? What new product scheduled for launch in 2021 is generating excitement and has the potential to disrupt the market? Is the focus on CGM for Type 2 diabetics warranted? Will the Type 2 patient population materialize as the major growth segment for CGM? What percentage of the Type 1 diabetes market will be pumpers in 18 to 24 months? Will Type 2 insulin users consider using pumps? How many? To answer these and other questions, Blueshift will gather data and issue a market research report from independent sources in the following areas: Endocrinologists, Nurse educators, Diabetes centers, Diabetes sales channel, Competitors, and Industry specialists. 

 

Companies: Abbott Laboratories (ABT), Dexcom Inc. (DXCM), Insulet Corporation (PODD), Medtronic plc (MDT), Senseonics Holdings Inc. (SENS), Tandem Diabetes Care Inc. (TNDM)

 

Research Begins: May 17, 2021

 

To see other ideas Blueshift Research is currently working on, please click here.

 

Blueshift Research’s sister company, Intro-act, has launched the Intro-act Scorecard, the C-suite’s standard, ongoing measure of corporate investor engagement.

 

The Scorecard optimizes the ROI on corporate access by measuring: Concentration, Directionality, Breadth, Impact, Depth, and Duration

 

See the sample Scorecard. Watch the Scorecard video.